system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Aged, Antigens, CD1d, Biomarkers, Tumor, Carcinoma, Renal Cell, Chi-Square Distribution, Disease Progression, Disease-Free Survival, Female, Gene Expression Profiling, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Oligonucleotide Array Sequence Analysis, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies, Risk Factors, Time Factors, Tissue Array Analysis, Treatment Outcome, Up-Regulation.
user
Is cD1d expression in renal cell carcinoma associated with higher relapse rates , poorer cancer-specific and overall survival? Context: We hypothesised that CD1d expression in renal cell carcinoma (RCC) may play a role in modifying the host immune response. Our aims were to investigate the expression of CD1d and to correlate this with histopathology and clinical outcomes in a cohort study of patients with RCC. Gene expression and tissue microarray studies on a panel of RCC tissue were performed. Clinicopathological correlation was analysed using χ(2)/Fisher's exact test. Relapse-free survival, cancer-specific survival and overall survival were calculated for both CD1d high and low expressors. Survival outcomes were estimated with the Kaplan-Meier method and compared using Cox regression analysis. Gene expression microarray showed significant expression of CD1d in RCC versus normal renal tissue. By immunohistochemistry, we found that CD1d expression significantly associated with tumour stage/grade, higher relapse rates, poorer cancer-specific and overall survival.
assistant
CD1d expression on RCC correlated with aggressive disease and poorer clinical outcomes. Final Decision: yes